Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Nymox Pharmaceutical Corporation recently announced that it has completed enrollment of benign prostatic hyperplasia (BPH) patients in a phase III study (NX02-0020) of NX-1207 in the US. The study enrolled patients who were a part of previously conducted NX-1207 studies. The efficacy results from the study are expected to be reported by the end of 2012.

A few days ago, the company had received a positive feedback from the Safety Monitoring Committee meeting which reported that there was no significant safety concerns associated with NX-1207.

The use of NX-1207 was found to be safer than currently approved BPH drugs which are associated with sexual or blood pressure related side effects. The injectable NX-1207 is easy to administer and does not require the use of any type of sedation measures or catheterization.

NX-1207 is in phase III development both in the US and the Europe. In Europe, the company has a licensing agreement with Recordati S.p.A. Recordati is sponsoring a recently initiated phase III study in Europe.

BPH is commonly diagnosed in middle aged and older men. According to the company, approximately 50% of middle aged men exhibit signs of prostatic hyperplasia.

We note that the BPH market is pretty crowded with players like Merck’s (MRK - Analyst Report) Proscar (finasteride), GlaxoSmithKline’s (GSK - Analyst Report) Avodart (dutasteride) and Jalyn (dutasteride + tamsulosin), Sanofi’s (SNY - Analyst Report) Uroxatral (alfuzosin HCl) and Watson Pharmaceuticals’ Rapaflo (silodosin) among others.

Recommendation

We currently have a Neutral recommendation on Nymox. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%